CytoDyn Begins GMP Manufacturing of Its First-In-Class AIDS Drug - CytoDyn, Inc.(Pink Sheets: CYDY) has begun GMP manufacturing and humanization of Cytolin(C), a monoclonal antibody that uses the human immune system to control HIV infection.
The murine version of this product, for which there is...
Induction Therapy With Trizivir Plus Efavirenz or Lopinavir/ritonavir Followed by Trizivir Alone in Naive HIV- _ Induction Therapy With Trizivir Plus Efavirenz or Lopinavir/ritonavir Followed by Trizivir Alone in Naive HIV-.
Aspen soars on news of AIDS-drug tender CAPE TOWN The share price of Aspen Pharmacare, SAs biggest manufacturer of generic medicines, climbed 7,18% yesterday on news it had won the lions share of the governments new R3,6bn AIDS-drug tender.The two-year contract is the backbone...
Self-confessed bid rigger Adcock wins new government contract By Slindile Khanyile Durban Adcock Ingram has won a government contract worth more than R500 million, despite admitting recently that it had been involved in rigging bids for state tenders.Adcock has been granted 20.9 percent of the total...
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating - Once-daily dosing with enteric-coated tablet produced robust antiviral activity - SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.today announced additional positive results from its completed Phase 2a proof-of...
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating - Once-daily dosing with enteric-coated tablet produced robust antiviral activity - - RDEA806 was well tolerated during one week of dosing in HIV patients - SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.(Nasdaq: RDEA...
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc.(Nasdaq: RDEA) today announced additional positive results from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, its novel investigational non...
Aids drug tender awarded to 6 firms The Department of Health has awarded a R3, 615 billion tender to six suppliers to over a period of two years to supply anti-retrovirals.Spokesman Sibani Mngadi said this tender was awarded to support the implementation of the...
FDA Announces New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Ag - The Kaletra (lopinavir/ritonavir) Tablet and Oral Solution labels were updated to include dosing recommendations for pediatric patients 14 days to 6 months of age and from 12 to 18 years of age.In addition, information regarding oral...
Antiretroviral Intensification Does Not Reduce HIV-1 Viremia in Patients Suppressed on Standard Combination Th XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Reported by Jules Levin XVII HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Frank Maldarelli HIV Drug Resistance Program NCI-Frederick, NIH, USA...
Report on the XV11 International Drug Resistance Workshop, June 10-14, 2008, Sitges, Spain XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Mark A Wainberg McGill University AIDS Centre Montreal, Canada 1.Integrase Inhibitors (resistance) 2.
New drugs- NNRTI inhibitors: IDX899; Bevirimat: HIV...
New Index Explains Why Some Drugs Work Better Than Others Against Hiv Johns Hopkins Medicine Media Relations and Public Affairs Media contact: David March 410-955-1534; mailto:dmarch1@jhmi.edu A team of AIDS experts at Johns Hopkins has found a simple mathematical equation that accurately explains how well...
TopAbstracts in AIDS and HIV 06/23/2008 TopAbstracts in AIDS and HIV are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed...
Tibotec Analysis: Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR) XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Reported by Jules Levin XVII HIV Drug Resistance Workshop June 10-14, 200 Sitges, Spain Gaston Picchio,1 Johan Vingerhoets,2 Neil Parkin,3 Hilde Azijn,2 Marie...
Intensifying Standard Regimens Does Not Lower Residual Plasma HIV RNA XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain XVII International HIV Drug Resistance Workshop June 10-14, 2008, Sitges, Spain Mark Mascolini Adding efavirenz or lopinavir/ritonavir to an already...
Virco Etravirine Clinical Cutoffs XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Reported by Jules Levin XVII HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Exploring Etravirine Resistance Among Recent Routine Clinical Samples...
Increased Phenotypic Susceptibility to Etravirine in HIV-1 with NRTI Resistance XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Reported by Jules Levin 17th HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain J Benhamida, E Coakley, NT Parkin, C Chappey Monogram Biosciences, South...
Boosted protease inhibitors have 60% lower risk of resistance compared with other classes Patients who start antiretroviral therapy with a combination based on a "boosted" protease inhibitor are less likely to develop drug-resistant HIV than patients who take therapy based on either a non-nucleoside reverse transcriptase...
Low-Level Pretreatment NNRTI Mutation May Imperil Virologic Response XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain XVII International HIV Drug Resistance Workshop June 10-14, 2008, Sitges, Spain Mark Mascolini South African women with typically undetectable levels of the K103N...
HIV Patients Taking Efavirenz (Sustiva) Experience Fewer Oral Lesions than Those on Protease Inhibitors Oral lesions have an important prognostic value for HIV patients, as they may be an indicator of immune decline and disease progression.However, the prevalence of such lesions in patients receiving HAART regimens that include efavirenz ...
Cumulative Resistance Catalog Gives Clearer Picture of Salvage Picks XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain XVII International HIV Drug Resistance Workshop June 10-14, 2008, Sitges, Spain Mark Mascolini Accounting for all resistance mutations that ever evolved during a...
Long-term Efficacy and Tolerability of Regimens Containing Efavirenz (Sustiva) and Nevirapine (Viramune) Regim Because of their favorable toxicity profile, low price, and ease of use, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz (Sustiva) and nevirapine (Viramune) are frequently used as part of antiretroviral therapy...
NNRTI Mutation Rates With Failing EFV vs NVP in EuroSIDA XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain XVII International HIV Drug Resistance Workshop June 10-14, 2008, Sitges, Spain Mark Mascolini New nonnucleoside (NNRTI) mutations kept piling up as people...
HAART Regimen Changes Due to Drug Toxicities in HIV Positive People with Virological Suppression HAART Regimens Changes Due to Drug Toxicities in HIV Positive People with Virological Suppression Many prior studies have looked at switching various antiretroviral drug regimens due to virological failure or side effects, but few...
In Vitro Cross-Resistance Profile for a Next-Generation NNRT I: IDX899 XVII International HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain Reported by Jules Levin 17th HIV Drug Resistance Workshop June 10-14, 2008 Sitges, Spain JJ Jakubik, C Chapron, L Hubbard, M Seifer, DN Standring Idenix...
